Skip to content
10-Q

Quarterly Report

Nautilus Biotechnology, Inc. NAUT

0001808805-26-000022

← back to feed
Filed
Apr 28, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 127.08M sh
Shares Diluted Q1 2026 · Mar 31, 2026 126.63M sh
Shares Diluted Q1 2026 · Mar 31, 2025 126.14M sh
Capex Q1 2026 · Mar 31, 2026 $510K
Capex Q1 2026 · Mar 31, 2025 $219K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.1M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.94M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $12.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $144.42M
Stockholders Equity Q1 2026 · Dec 31, 2025 $156.97M
Stockholders Equity Q1 2026 · Mar 31, 2025 $194.44M
Stockholders Equity Q1 2026 · Dec 31, 2024 $208.73M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.34M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.95M
Total Liabilities Q1 2026 · Mar 31, 2026 $33.36M
Total Liabilities Q1 2026 · Dec 31, 2025 $34.14M
Current Assets Q1 2026 · Mar 31, 2026 $98.83M
Current Assets Q1 2026 · Dec 31, 2025 $105.96M
Total Assets Q1 2026 · Mar 31, 2026 $177.78M
Total Assets Q1 2026 · Dec 31, 2025 $191.11M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.12
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.13
Eps Basic Q1 2026 · Mar 31, 2026 −$0.12
Eps Basic Q1 2026 · Mar 31, 2025 −$0.13
Sga Expense Q1 2026 · Mar 31, 2026 $6.42M
Sga Expense Q1 2026 · Mar 31, 2025 $7.31M
Rd Expense Q1 2026 · Mar 31, 2026 $9.71M
Rd Expense Q1 2026 · Mar 31, 2025 $11.54M
Net Income Q1 2026 · Mar 31, 2026 −$14.7M
Net Income Q1 2026 · Mar 31, 2025 −$16.61M